🇺🇸 FDA
Pipeline program

Telitacicept

RC18G007

Phase 3 mab active

Quick answer

Telitacicept for Primary Sjogren's Disease is a Phase 3 program (mab) at Vor Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Vor Biopharma
Indication
Primary Sjogren's Disease
Phase
Phase 3
Modality
mab
Status
active

Clinical trials